Hepatitis C: Magnitude of the problem

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Key Points 1. End-stage liver disease associated with hepatitis C virus (HCV) infection has become the leading indication for liver transplantation in the United States. 2. Patients with end-stage liver disease caused by HCV may have such associated comorbidities as chronic alcoholism, steatosis, or coinfection with human immunodeficiency virus 1 or other hepatitis viruses. These comorbidities may accelerate disease progression. 3. As chronic hepatitis C progresses to cirrhosis, the risk for the development of hepatocellular carcinoma increases; this poses difficult management problems. 4. As patients who underwent transplantation for end-stage liver disease caused by HCV infection are followed up long term, it has become clear that patient and graft survival are decreased compared with HCV-negative patients or those with cholestatic: liver disorders. 5. Risk factors associated with a worse outcome after transplantation include host, viral, donor, and posttransplantation factors. 6. Major challenges to be addressed in the future include delineation of the optimal antiviral therapy and how to handle the need to perform retransplantation on patients who develop graft dysfunction as a result of HCV recurrence.

Original languageEnglish (US)
JournalLiver Transplantation
Volume8
Issue number10 SUPPL. 1
DOIs
StatePublished - Oct 1 2002

Fingerprint

Hepatitis C
Hepacivirus
End Stage Liver Disease
Virus Diseases
Comorbidity
Transplantation
Hepatitis Viruses
Graft Survival
Chronic Hepatitis C
Coinfection
Liver Transplantation
Alcoholism
Antiviral Agents
Disease Progression
HIV-1
Hepatocellular Carcinoma
Fibrosis
Tissue Donors
Transplants
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Hepatitis C : Magnitude of the problem. / Rakela, Jorge; Vargas, Hugo E.

In: Liver Transplantation, Vol. 8, No. 10 SUPPL. 1, 01.10.2002.

Research output: Contribution to journalArticle

@article{bd9d839bf0e44265b85ed31e91fc5d6d,
title = "Hepatitis C: Magnitude of the problem",
abstract = "Key Points 1. End-stage liver disease associated with hepatitis C virus (HCV) infection has become the leading indication for liver transplantation in the United States. 2. Patients with end-stage liver disease caused by HCV may have such associated comorbidities as chronic alcoholism, steatosis, or coinfection with human immunodeficiency virus 1 or other hepatitis viruses. These comorbidities may accelerate disease progression. 3. As chronic hepatitis C progresses to cirrhosis, the risk for the development of hepatocellular carcinoma increases; this poses difficult management problems. 4. As patients who underwent transplantation for end-stage liver disease caused by HCV infection are followed up long term, it has become clear that patient and graft survival are decreased compared with HCV-negative patients or those with cholestatic: liver disorders. 5. Risk factors associated with a worse outcome after transplantation include host, viral, donor, and posttransplantation factors. 6. Major challenges to be addressed in the future include delineation of the optimal antiviral therapy and how to handle the need to perform retransplantation on patients who develop graft dysfunction as a result of HCV recurrence.",
author = "Jorge Rakela and Vargas, {Hugo E}",
year = "2002",
month = "10",
day = "1",
doi = "10.1053/jlts.2002.35855",
language = "English (US)",
volume = "8",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "10 SUPPL. 1",

}

TY - JOUR

T1 - Hepatitis C

T2 - Magnitude of the problem

AU - Rakela, Jorge

AU - Vargas, Hugo E

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Key Points 1. End-stage liver disease associated with hepatitis C virus (HCV) infection has become the leading indication for liver transplantation in the United States. 2. Patients with end-stage liver disease caused by HCV may have such associated comorbidities as chronic alcoholism, steatosis, or coinfection with human immunodeficiency virus 1 or other hepatitis viruses. These comorbidities may accelerate disease progression. 3. As chronic hepatitis C progresses to cirrhosis, the risk for the development of hepatocellular carcinoma increases; this poses difficult management problems. 4. As patients who underwent transplantation for end-stage liver disease caused by HCV infection are followed up long term, it has become clear that patient and graft survival are decreased compared with HCV-negative patients or those with cholestatic: liver disorders. 5. Risk factors associated with a worse outcome after transplantation include host, viral, donor, and posttransplantation factors. 6. Major challenges to be addressed in the future include delineation of the optimal antiviral therapy and how to handle the need to perform retransplantation on patients who develop graft dysfunction as a result of HCV recurrence.

AB - Key Points 1. End-stage liver disease associated with hepatitis C virus (HCV) infection has become the leading indication for liver transplantation in the United States. 2. Patients with end-stage liver disease caused by HCV may have such associated comorbidities as chronic alcoholism, steatosis, or coinfection with human immunodeficiency virus 1 or other hepatitis viruses. These comorbidities may accelerate disease progression. 3. As chronic hepatitis C progresses to cirrhosis, the risk for the development of hepatocellular carcinoma increases; this poses difficult management problems. 4. As patients who underwent transplantation for end-stage liver disease caused by HCV infection are followed up long term, it has become clear that patient and graft survival are decreased compared with HCV-negative patients or those with cholestatic: liver disorders. 5. Risk factors associated with a worse outcome after transplantation include host, viral, donor, and posttransplantation factors. 6. Major challenges to be addressed in the future include delineation of the optimal antiviral therapy and how to handle the need to perform retransplantation on patients who develop graft dysfunction as a result of HCV recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0036795544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036795544&partnerID=8YFLogxK

U2 - 10.1053/jlts.2002.35855

DO - 10.1053/jlts.2002.35855

M3 - Article

C2 - 12362291

AN - SCOPUS:0036795544

VL - 8

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 10 SUPPL. 1

ER -